Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space. Viking reported positive results for its new obesity pill,
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.
Viking Therapeutics surges after presenting ‘promising’ obesity drug data
Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental
Viking Therapeutics Jumps On Latest Obesity Drug Data
Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher doses. Viking stock jumped early Monday, but came well off premarket highs.
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug,
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
SchaeffersResearch.com1d
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
Viking Therapeutics, Roblox, Trump Media: 3 Stocks In Focus
In its latest study, Viking Therapeutics (VKTX) has found promising early results in a trial for its GLP-1 weight-loss drug.
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
bovnews5d
Why Viking Therapeutics Inc (VKTX) Stock is Currently 7.51% Above from Its 20-Day SMA?
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $71.75 which represents a decrease of $-1.60 or -2.18% from the prior close of $73.35. The stock opened at $71 and ...
Morningstar1d
Viking Therapeutics Inc VKTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...